BACKGROUND: Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. After the publication of the first guidelines for this technology in the JEADV in 2014, this technology has maintained additional promise in the treatment of other severe and refractory conditions in a multidisciplinary setting. It has confirmed recognition in well-known documented conditions such as graft-vs.-host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection including lung, heart and liver and to a lesser extent inflammatory bowel disease. MATERIALS AND METHODS: In order to further provide recognized expert practical guidelines for the use of this technology for all indications, the European Dermatology Forum (EDF) again proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task. All authors had the opportunity to review each contribution as it was added. RESULTS AND CONCLUSION: These updated 2020 guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion. The guidelines were divided into two parts: PART I covers Cutaneous T-cell lymphoma, chronic graft-vs.-host disease and acute graft-vs.-host disease, while PART II will cover scleroderma, solid organ transplantation, Crohn's disease, use of ECP in paediatric patients, atopic dermatitis, type 1 diabetes, pemphigus, epidermolysis bullosa acquisita and erosive oral lichen planus.

3rd Faculty of Medicine Charles University Prague Czech Republic

Crown Princess Victoria Children's Hospital and Division of Pediatrics Department of Biomedical and Clinical Sciences University Hospital Linköping University Linköping Sweden

Department Dermatology and Venereology Otto von Guericke University Magdeburg Germany

Department of Cardiac Surgery Medical University of Vienna Vienna Austria

Department of Clinical Immunology and Transfusion Medicine Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden

Department of Dermatology and Venerology Helios Klinikum Krefeld Krefeld Germany

Department of Dermatology Medical University of Graz Graz Austria

Department of Dermatology Medical University of Vienna Vienna Austria

Department of Dermatology University Clinics Schleswig Holstein Kiel Germany

Department of Dermatology University Hospital München Germany

Department of Thoracic Surgery Medical University Vienna Vienna Austria

Departments of Dermatology Venereology Allergology and Immunology Dessau Medical Center Brandenburg Medical School Theodor Fontane Dessau Germany

Dermatology Department University of Brescia Italy Brescia Italy

Division of Dermatology University of Alberta Edmonton Canada

Faculty of Biology and Medicine University of Lausanne and Department of Dermatology Lausanne University Hospital CHUV Lausanne Switzerland

FRCP St John's Institution of Dermatology Guy's and St Thomas' NHS Foundation Trust London United Kingdom

FRCPath The Rotherham NHA Foundation Trust Rotherham United Kingdom

Hautklinik Städtisches Klinikum Karlsruhe Karlsruhe Germany

Hospital Saint Louis Université de Paris Paris France

LKH Univ Klinikum Graz Division of Haematology Medical University of Graz Graz Austria

National and Kapodistrian University of Athens Athens Greece

Onco Hematology Department Hautepierre Hospital Strasbourg France

Translational and Clinical Research Institute Newcastle University Great North Children's Hospital Newcastle upon Tyne Newcastle University Newcastle upon Tyne United Kingdom

University Clinic for Dermatology Johannes Wesling Medical Centre UKRUB University of Bochum Minden Germany

University Hospital Birmingham Birmingham United Kingdom

Vanderbilt University Medical Center Department of Dermatology Nashville Tennessee USA

Zobrazit více v PubMed

Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989–2003. PubMed

Zhou XA, Choi J. Photopheresis: advances and use in systemic sclerosis. Curr Rheumatol Rep 2017; 19: 31. PubMed

Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953–1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15: 276–283. PubMed

Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir‐Gurman A et al Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897–1905. PubMed

Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139–153. PubMed

Scussel‐Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR et al Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81: 154–167. PubMed

De Martinis M, Ciccarelli F, Sirufo MM, Ginaldi L. An overview of environmental risk factors in systemic sclerosis. Expert Rev Clin Immunol 2016; 12: 465–478. PubMed

Artlett CM, Smith JB, Jimenez SA. New perspectives on the etiology of systemic sclerosis. Mol Med Today 1999; 5: 74–78. PubMed

French LE, Alcindor T, Shapiro M, McGinnis KS, Margolis DJ, Porter D et al Identification of amplified clonal T cell populations in the blood of patients with chronic graft‐versus‐host disease: positive correlation with response to photopheresis. Bone Marrow Transplant 2002; 30: 509–515. PubMed

Marie I, Cordel N, Lenormand B, Hellot MF, Levesque H, Courtois H et al Clonal T cells in the blood of patients with systemic sclerosis. Arch Dermatol 2005; 141: 88–89. PubMed

Kreuter A, Hoxtermann S, Tigges C, Hahn SA, Altmeyer P, Gambichler T. Clonal T‐cell populations are frequent in the skin and blood of patients with systemic sclerosis. Br J Dermatol 2009; 161: 785–790. PubMed

Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA et al Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 1992; 128: 337–346. PubMed

Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema R et al Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41: 915–922. PubMed

Knobler RM, French LE, Kim Y, Bisaccia E, Graninger W, Nahavandi H et al A randomized, double‐blind, placebo‐controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2006; 54: 793–799. PubMed

Muellegger RR, Hofer A, Salmhofer W, Soyer HP, Kerl H, Wolf P. Extended extracorporeal photochemotherapy with extracorporeal administration of 8‐methoxypsoralen in systemic sclerosis. An Austrian single‐center study. Photodermatol Photoimmunol Photomed 2000; 16: 216–223. PubMed

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L et al Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017; 2: 11–18. PubMed PMC

Papp G, Horvath IF, Gyimesi E, Barath S, Vegh J, Szodoray P et al The assessment of immune‐regulatory effects of extracorporeal photopheresis in systemic sclerosis: a long‐term follow‐up study. Immunol Res 2016; 64: 404–411. PubMed

Papp G, Barath S, Szegedi A, Szodoray P, Zeher M. The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol 2012; 31: 1293–1299. PubMed

Topuzoglu S, Knobler R, Movadat O, Petkov V, Foedinger D, Just U et al Incidence of lung cancer in patients with systemic sclerosis treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 2015; 31: 175–183. PubMed

Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C et al Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta‐analysis of observational studies. Rheumatology (Oxford) 2013; 52: 143–154. PubMed

Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta‐analysis of population‐based cohort studies. Arthritis Rheum 2013; 65: 1913–1921. PubMed

Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R et al The Registry of the International Society for Heart and Lung Transplantation: twenty‐seventh official adult lung and heart‐lung transplant report–2010. J Heart Lung Transplant 2010; 29: 1104–1118. PubMed

Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M et al Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297–310. PubMed

Boehler A, Estenne M. Post‐transplant bronchiolitis obliterans. Eur Respir J 2003; 22: 1007–1018. PubMed

Mullen JC, Oreopoulos A, Lien DC, Bentley MJ, Modry DL, Stewart K et al A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007; 26: 504–510. PubMed

Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long‐term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36–41. PubMed

Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6: 47–53. PubMed

MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK et al Early antithymocyte globulin therapy improves survival in patients with steroid‐resistant acute graft‐versus‐host disease. Biol Blood Marrow Transplant 2002; 8: 40–46. PubMed

Andreu G, Achkar A, Couetil JP, Guillemain R, Heshmati F, Amrein C et al Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant 1995; 14: 793–796. PubMed

Slovis BS, Loyd JE, King LE, Jr . Photopheresis for chronic rejection of lung allografts. N Engl J Med 1995; 332: 962. PubMed

O'Hagan AR, Stillwell PC, Arroliga A, Koo A. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999; 115: 1459–1462. PubMed

Villanueva J, Bhorade SM, Robinson JA, Husain AN, Garrity ER, Jr . Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000; 5: 44–47. PubMed

Salerno CT, Park SJ, Kreykes NS, Kulick DM, Savik K, Hertz MI et al Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg 1999; 117: 1063–1069. PubMed

Benden C, Speich R, Hofbauer GF, Irani S, Eich‐Wanger C, Russi EW et al Extracorporeal photopheresis after lung transplantation: a 10‐year single‐center experience. Transplantation 2008; 86: 1625–1627. PubMed

Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 424–431. PubMed

Jaksch P, Scheed A, Keplinger M, Ernst MB, Dani T, Just U et al A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2012; 31: 950–957. PubMed

Greer M, Dierich M, De Wall C, Suhling H, Rademacher J, Welte T et al Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant 2013; 13: 911–918. PubMed

Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc 2007; 39: 213–217. PubMed

Piloni D, Morosini M, Magni S, Balderacchi A, Scudeller L, Cova E et al Analysis of long term CD4+CD25highCD127‐ T‐reg cells kinetics in peripheral blood of lung transplant recipients. BMC Pulm Med 2017; 17: 102. PubMed PMC

Baskaran G, Tiriveedhi V, Ramachandran S, Aloush A, Grossman B, Hachem R et al Efficacy of extracorporeal photopheresis in clearance of antibodies to donor‐specific and lung‐specific antigens in lung transplant recipients. J Heart Lung Transplant 2014; 33: 950–956. PubMed PMC

Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare‐Eligible Recipients of Lung Allografts. active, not recruiting. 2019.

Astor TL, Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg 2003; 7(4 Suppl): 20–24. PubMed

Knobler R, Berlin G, Calzavara‐Pinton P, Greinix H, Jaksch P, Laroche L et al Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 2014; 28(Suppl 1): 1–37. PubMed PMC

Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ et al The Registry of the International Society for Heart and Lung Transplantation: Thirty‐fourth Adult Heart Transplantation Report‐2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant 2017; 36: 1037–1046. PubMed

Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008; 117: 2131–2141. PubMed

Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R et al Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339: 1744–1751. PubMed

Barr ML, Baker CJ, Schenkel FA, McLaughlin SN, Stouch BC, Starnes VA et al Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant 2000; 14: 162–166. PubMed

Dall'Amico R, Montini G, Murer L, Andreetta B, Zacchello G, Gambino A et al Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. Int J Artif Organs 2000; 23: 49–54. PubMed

Lehrer MS, Rook AH, Tomaszewski JE, DeNofrio D. Successful reversal of severe refractory cardiac allograft rejection by photopheresis. J Heart Lung Transplant 2001; 20: 1233–1236. PubMed

Kirklin JK, Brown RN, Huang ST, Naftel DC, Hubbard SM, Rayburn BK et al Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006; 25: 283–288. PubMed

Dieterlen MT, Bittner HB, Pierzchalski A, Dhein S, Mohr FW, Barten MJ. Immunological monitoring of extracorporeal photopheresis after heart transplantation. Clin Exp Immunol 2014; 176: 120–128. PubMed PMC

Carlo WF, Pearce FB, George JF, Tallaj JA, McGiffin DC, Marques MB et al Single‐center experience with extracorporeal photopheresis in pediatric heart transplantation. J Heart Lung Transplant 2014; 33: 624–628. PubMed

Savignano C, Rinaldi C, Tursi V, Dolfini C, Isola M, Livi U et al Extracorporeal photochemotherapy in heart transplant rejection: A single‐center experience. Transfus Apher Sci 2017; 56: 520–524. PubMed

Marques MB, Schwartz J. Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apher 2011; 26: 146–151. PubMed

Alfred A, Taylor PC, Dignan F, El‐Ghariani K, Griffin J, Gennery AR et al The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol 2017; 177: 287–310. PubMed PMC

Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly‐Smith L, Delaney M et al Guidelines on the Use of Therapeutic Apheresis in Clinical Practice‐Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The seventh special issue. J Clin Apher 2016; 31: 149–162. PubMed

Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S et al The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914–956. PubMed

Hivelin M, Siemionow M, Grimbert P, Lantieri L. Extracorporeal photopheresis: from solid organs to face transplantation. Transpl Immunol 2009; 21: 117–128. PubMed

Lehrer MS, Ruchelli E, Olthoff KM, French LE, Rook AH. Successful reversal of recalcitrant hepatic allograft rejection by photopheresis. Liver Transpl 2000; 6: 644–647. PubMed

Urbani L, Mazzoni A, Catalano G, De Simone P, Vanacore R, Pardi C et al The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. Transplant Proc 2004; 36: 3068–3070. PubMed

Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C et al A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen‐month mortality in HCV recipients transplanted with aged livers. Transplantation 2008; 86: 1666–1671. PubMed

Urbani L, Mazzoni A, Colombatto P, Biancofiore G, Bindi L, Tascini C et al Potential applications of extracorporeal photopheresis in liver transplantation. Transplant Proc 2008; 40: 1175–1178. PubMed

Dall'Amico R, Murer L, Montini G, Andreetta B, Zanon GF, Zacchello G et al Successful treatment of recurrent rejection in renal transplant patients with photopheresis. J Am Soc Nephrol 1998; 9: 121–127. PubMed

Baron ED, Heeger PS, Hricik DE, Schulak JA, Tary‐Lehmann M, Stevens SR. Immunomodulatory effect of extracorporeal photopheresis after successful treatment of resistant renal allograft rejection. Photodermatol Photoimmunol Photomed 2001; 17: 79–82. PubMed

Wolfe JT, Tomaszewski JE, Grossman RA, Gottlieb SL, Naji A, Brayman KL et al Reversal of acute renal allograft rejection by extracorporeal photopheresis: a case presentation and review of the literature. J Clin Apher 1996; 11: 36–41. PubMed

Genberg H, Kumlien G, Shanwell A, Tyden G. Refractory acute renal allograft rejection successfully treated with photopheresis. Transplant Proc 2005; 37: 3288–3289. PubMed

Kusztal M, Klak R, Krajewska M, Boratynska M, Patrzalek D, Klinger M. Application of extracorporeal photopheresis in kidney transplant recipients: technical considerations and procedure tolerance. Transplant Proc 2011; 43: 2941–2942. PubMed

Kumlien G, Genberg H, Shanwell A, Tyden G. Photopheresis for the treatment of refractory renal graft rejection. Transplantation 2005; 79: 123–125. PubMed

Lamioni A, Carsetti R, Legato A, Landolfo A, Isacchi G, Emma F et al Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation 2007; 83: 1393–1396. PubMed

Jardine MJ, Bhandari S, Wyburn KR, Misra AK, McKenzie PR, Eris JM. Photopheresis therapy for problematic renal allograft rejection. J Clin Apher 2009; 24: 161–169. PubMed

Lai Q, Pretagostini R, Gozzer M, Cinti P, Meo D, Vita F et al Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody‐mediated renal transplant rejection: a 2‐year follow‐up. Transplant Proc 2011; 43: 1039–1041. PubMed

Urbani L, Mazzoni A, De Simone P, Catalano G, Coletti L, Petruccelli S et al Avoiding calcineurin inhibitors in the early post‐operative course in high‐risk liver transplant recipients: The role of extracorporeal photopheresis. J Clin Apher 2007; 22: 187–194. PubMed

Kusztal M, Koscielska‐Kasprzak K, Gdowska W, Zabinska M, Myszka M, Klak R et al Extracorporeal photopheresis as an antirejection prophylaxis in kidney transplant recipients: preliminary results. Transplant Proc 2011; 43: 2938–2940. PubMed

McKenna KE, Whittaker S, Rhodes LE, Taylor P, Lloyd J, Ibbotson S et al Evidence‐based practice of photopheresis 1987–2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol 2006; 154: 7–20. PubMed

Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R et al Guidelines on the use of therapeutic apheresis in clinical practice: evidence‐based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22: 106–175. PubMed

Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R et al Long‐term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244–250. PubMed

Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell 2010; 140: 859–870. PubMed PMC

Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF et al The second European evidence‐based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4: 28–62. PubMed

Reinisch W, Nahavandi H, Santella R, Zhang Y, Gasche C, Moser G et al Extracorporeal photochemotherapy in patients with steroid‐dependent Crohn's disease: a prospective pilot study. Aliment Pharmacol Ther 2001; 15: 1313–1322. PubMed

Reinisch W, Knobler R, Rutgeerts PJ, Ochsenkuhn T, Anderson F, von Tirpitz C et al Extracorporeal photopheresis (ECP) in patients with steroid‐dependent Crohn's disease: an open‐label, multicenter, prospective trial. Inflamm Bowel Dis 2013; 19: 293–300. PubMed PMC

Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti‐TNF‐alpha therapy. Aliment Pharmacol Ther 2011; 34: 1–10. PubMed

Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P et al Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open‐label pilot study. Inflamm Bowel Dis 2009; 15: 829–836. PubMed

Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C et al Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2017; 52: 811–817. PubMed PMC

Weitz M, Strahm B, Meerpohl JJ, Schmidt M, Bassler D. Extracorporeal photopheresis versus standard treatment for acute graft‐versus‐host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database Syst Rev 2015; 12: CD009759. PubMed PMC

Weitz M, Strahm B, Meerpohl JJ, Schmidt M, Bassler D. Extracorporeal photopheresis versus alternative treatment for chronic graft‐versus‐host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database Syst Rev 2015; 12: CD009898. PubMed PMC

Flinn A, Macheka S, Alfred A et alA national audit of paediatric extracorporeal photopheresis in the United Kingdom. European Society for Blood and Marrow Transplantation, EBMT Lisbon, Portugal, 18–21, March 2018 2018;available online; https://www.ebmt.org/ebmt/news/2018‐abstract‐book.

DeSimone RA, Schwartz J, Schneiderman J. Extracorporeal photopheresis in pediatric patients: Practical and technical considerations. J Clin Apher 2017; 32: 543–552. PubMed

Rangarajan HG, Punzalan RC, Camitta BM, Talano JA. The use of novel Therakos Cellex(R) for extracorporeal photopheresis in treatment of graft‐versus‐host disease in paediatric patients. Br J Haematol 2013; 163: 357–364. PubMed

DeSimone RA, Wontakal SN, Lyashchenko AK, Schwartz J. Acute mechanical hemolysis as a complication of extracorporeal photopheresis in a low‐weight child. J Clin Apher 2017; 32: 571–573. PubMed

Flinn AM, Roberts CF, Slatter MA, Skinner R, Robson H, Lawrence J et al Thymopoiesis following HSCT; a retrospective review comparing interventions for aGVHD in a pediatric cohort. Clin Immunol 2018; 193: 33–37. PubMed

Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I et al Guidelines for management of atopic dermatitis. J Dermatol 2009; 36: 563–577. PubMed

Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T et al S2k guideline on diagnosis and treatment of atopic dermatitis – short version. J Dtsch Dermatol Ges 2016; 14: 92–105. PubMed

Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B et al ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30: 729–747. PubMed

Darsow U, Wollenberg A, Simon D, Taieb A, Werfel T, Oranje A et al ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010; 24: 317–328. PubMed

Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004; 113: 756–763. PubMed

Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J et al Relation of CD4+CD25+ regulatory T‐cell suppression of allergen‐driven T‐cell activation to atopic status and expression of allergic disease. Lancet 2004; 363: 608–615. PubMed

Di Cesare A, Di Meglio P, Nestle FO. A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol 2008; 128: 2569–2571. PubMed

Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009; 123: 1004–1011. PubMed

Colver GB, Symons JA, Duff GW. Soluble interleukin 2 receptor in atopic eczema. BMJ 1989; 298: 1426–1428. PubMed PMC

Furue M, Koga T, Yamashita N. Soluble E‐selectin and eosinophil cationic protein are distinct serum markers that differentially represent clinical features of atopic dermatitis. Br J Dermatol 1999; 140: 67–72. PubMed

Legat FJ, Hofer A, Brabek E, Quehenberger F, Kerl H, Wolf P. Narrowband UV‐B vs medium‐dose UV‐A1 phototherapy in chronic atopic dermatitis. Arch Dermatol 2003; 139: 223–224. PubMed

Tzaneva S, Kittler H, Holzer G, Reljic D, Weber M, Honigsmann H et al 5‐Methoxypsoralen plus ultraviolet (UV) A is superior to medium‐dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 2010; 162: 655–660. PubMed

Wollenberg A, Barbarot S, Bieber T, Christen‐Zaech S, Deleuran M, Fink‐Wagner A et al Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657–682. PubMed

Wollenberg A, Barbarot S, Bieber T, Christen‐Zaech S, Deleuran M, Fink‐Wagner A et al Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850–878. PubMed

Simpson EL, Bieber T, Guttman‐Yassky E, Beck LA, Blauvelt A, Cork MJ et al Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348. PubMed

Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A et al Anti‐interleukin‐31 receptor a antibody for atopic dermatitis. N Engl J Med 2017; 376: 826–835. PubMed

Nygaard U, Vestergaard C, Deleuran M. Emerging treatment options in atopic dermatitis: systemic therapies. Dermatology 2017; 233: 344–357. PubMed

Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology 2017; 233: 333–343. PubMed

Prinz B, Nachbar F, Plewig G. Treatment of severe atopic dermatitis with extracorporeal photopheresis. Arch Dermatol Res 1994; 287: 48–52. PubMed

Hjuler KP, Vestergaard C, Deleuran M. A retrospective study of six cases of severe recalcitrant atopic dermatitis treated with long‐term extracorporeal photopheresis. Acta Derm Venereol 2010; 90: 635–636. PubMed

Mohla G, Horvath N, Stevens S. Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis. J Am Acad Dermatol 1999; 40(5 Pt 1): 780–782. PubMed

Wolf P, Georgas D, Tomi NS, Schempp CM, Hoffmann K. Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial. Photochem Photobiol Sci 2013; 12: 174–181. PubMed

Prinz B, Michelsen S, Pfeiffer C, Plewig G. Long‐term application of extracorporeal photochemotherapy in severe atopic dermatitis. J Am Acad Dermatol 1999; 40: 577–582. PubMed

Radenhausen M, Michelsen S, Plewig G, Bechara FG, Altmeyer P, Hoffmann K. Bicentre experience in the treatment of severe generalised atopic dermatitis with extracorporeal photochemotherapy. J Dermatol 2004; 31: 961–970. PubMed

Radenhausen M, von Kobyletzki G, Hoxtermann S, Altmeyer P, Hoffmann K. Activation markers in severe atopic dermatitis following extracorporeal photochemotherapy. Acta Derm Venereol 2003; 83: 49–50. PubMed

Richter HI, Billmann‐Eberwein C, Grewe M, Stege H, Berneburg M, Ruzicka T et al Successful monotherapy of severe and intractable atopic dermatitis by photopheresis. J Am Acad Dermatol 1998; 38: 585–588. PubMed

Sand M, Bechara FG, Sand D, Radenhausen M, Tomi NS, Altmeyer P et al Extracorporeal photopheresis as a treatment for patients with severe, refractory atopic dermatitis. Dermatology 2007; 215: 134–138. PubMed

Rubegni P, Poggiali S, Cevenini G, D'Ascenzo G, Perrone A, Flori ML et al Long term follow‐up results on severe recalcitrant atopic dermatitis treated with extracorporeal photochemotherapy. J Eur Acad Dermatol Venereol 2013; 27: 523–526. PubMed

Koppelhus U, Poulsen J, Grunnet N, Deleuran MS, Obitz E. Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross‐over study comparing two efficient treatment modalities. Front Med (Lausanne) 2014; 1: 33. PubMed PMC

Knobler R. Photopheresis and the red man syndrome. Dermatology 1995; 190: 97–98. PubMed

Zachariae H, Bjerring P, Brodthagen U, Sogaard H. Photopheresis in the red man or pre‐Sezary syndrome. Dermatology 1995; 190: 132–135. PubMed

Hofer A, Mullegger R, Kerl H, Wolf P. Extracorporeal photochemotherapy for the treatment of erythrodermic pityriasis rubra pilaris. Arch Dermatol 1999; 135: 475–476. PubMed

Wolf P, Mullegger R, Cerroni L, Aigner R, Fueger G, Hofler G et al Photoaccentuated erythroderma associated with CD4+ T lymphocytopenia: successful treatment with 5‐methoxypsoralen and UVA, interferon alfa‐2b, and extracorporeal photopheresis. J Am Acad Dermatol 1996; 35(2 Pt 2): 291–294. PubMed

Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN et al Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71: 327–349. PubMed PMC

Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG et al Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol 2014; 71: 1218–1233. PubMed PMC

Wolf P.Extracorporeal photopheresis in atopic dermatitis. Data presented at the 34th Annual Meeting of the American Society for Photobiology, Burlingame, CA, June 20–25, 2008. 2008.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216. PubMed

Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among patients with atopic eczema. Br J Dermatol 2006; 154: 719–725. PubMed

Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality‐of‐life instruments 1985–2010. PLoS One 2011; 6: e17520. PubMed PMC

Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T‐cell lymphoma. J Invest Dermatol 2006; 126: 2217–2223. PubMed PMC

Diabetes C, Complications Trial Research G , Nathan DM, Genuth S, Lachin J, Cleary P et al The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986. PubMed

Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin‐dependent diabetes mellitus. N Engl J Med 1994; 330: 15–18. PubMed

Lind M, Svensson AM, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2015; 372: 880–881. PubMed

Lind M, Svensson AM, Kosiborod M, Gudbjornsdottir S, Pivodic A, Wedel H et al Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371: 1972–1982. PubMed

Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM et al Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register‐based cohort study. Lancet 2018; 392: 477–486. PubMed PMC

Madsbad S, Alberti KG, Binder C, Burrin JM, Faber OK, Krarup T et al Role of residual insulin secretion in protecting against ketoacidosis in insulin‐dependent diabetes. Br Med J 1979; 2: 1257–1259. PubMed PMC

Steffes MW, Sibley S, Jackson M, Thomas W. Beta‐cell function and the development of diabetes‐related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832–836. PubMed

Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 2007; 3: 758–768. PubMed

Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet 2016; 387: 2340–2348. PubMed PMC

Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011; 57: 168–175. PubMed

Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P et al Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663–670. PubMed

Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P et al Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo‐controlled double blind trial. Diabetologia 1998; 41: 1040–1046. PubMed

Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D et al A single course of anti‐CD3 monoclonal antibody hOKT3gamma1(Ala‐Ala) results in improvement in C‐peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54: 1763–1769. PubMed PMC

Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al Insulin needs after CD3‐antibody therapy in new‐onset type 1 diabetes. N Engl J Med 2005; 352: 2598–2608. PubMed

Pescovitz MD, Greenbaum CJ, Krause‐Steinrauf H, Becker DJ, Gitelman SE, Goland R et al Rituximab, B‐lymphocyte depletion, and preservation of beta‐cell function. N Engl J Med 2009; 361: 2143–2152. PubMed PMC

Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M et al GAD treatment and insulin secretion in recent‐onset type 1 diabetes. N Engl J Med 2008; 359: 1909–1920. PubMed

Tavira B, Barcenilla H, Wahlberg J, Achenbach P, Ludvigsson J, Casas R. Intralymphatic Glutamic Acid Decarboxylase‐Alum Administration Induced Th2‐Like‐Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes. J Diabetes Res 2018; 2018: 9391845. PubMed PMC

Ludvigsson J. Author's reply to Dayal: "Therapies to preserve beta‐cell function in type 1 diabetes". Drugs 2016; 76: 627. PubMed

Ludvigsson J. Therapies to preserve beta‐cell function in type 1 diabetes. Drugs 2016; 76: 169–185. PubMed

Xia CQ, Chernatynskaya A, Lai Y, Campbell KA, Clare‐Salzler MJ. Experimental extracorporeal photopheresis therapy significantly delays the development of diabetes in non‐obese diabetic mice. Clin Immunol 2010; 135: 374–383. PubMed

Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001; 85: 149–154. PubMed PMC

Rook AH, Jegasothy BV, Heald P, Nahass GT, Ditre C, Witmer WK et al Extracorporeal photochemotherapy for drug‐resistant pemphigus vulgaris. Ann Intern Med 1990; 112: 303–305. PubMed

Gollnick HP, Owsianowski M, Taube KM, Orfanos CE. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol 1993; 28: 122–124. PubMed

Wollina U, Lange D, Looks A. Short‐time extracorporeal photochemotherapy in the treatment of drug‐resistant autoimmune bullous diseases. Dermatology 1999; 198: 140–144. PubMed

Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992; 26(5 Pt 1): 779–780. PubMed

Azana JM, de Misa RF, Harto A, Ledo A, Espana A. Severe pemphigus foliaceus treated with extracorporeal photochemotherapy. Arch Dermatol 1997; 133: 287–289. PubMed

Sanli H, Akay BN, Ayyildiz E, Anadolu R, Ilhan O. Remission of severe autoimmune bullous disorders induced by long‐term extracorporeal photochemotherapy. Transfus Apher Sci 2010; 43: 353–359. PubMed

Licht‐Mbalyohere AHA, Stadler R. Extracorporeal photochemotherapy of therapy‐refractory cases of systemic lupus erythematosus with urticarial vasculitis and pemphigus foliaceus. Eur J Dermatol 1996; 6: 106–109.

Harman KE, Albert S, Black MM. British Association of D. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926–937. PubMed

Daniel BS, Hertl M, Werth VP, Eming R, Murrell DF. Severity score indexes for blistering diseases. Clin Dermatol 2012; 30: 108–113. PubMed PMC

Miller JL, Stricklin GP, Fine JD, King LE, Arzubiaga MC, Ellis DL. Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy. Br J Dermatol 1995; 133: 467–471. PubMed

Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997; 136: 415–420. PubMed

Camara A, Becherel PA, Bussel A, Lagrange S, Chosidow O, Joly P et al Resistant acquired bullous epidermolysis with severe ocular involvement: the success of extracorporeal photochemotherapy. Ann Dermatol Venereol 1999; 126(8–9): 612–615. PubMed

Becherel PA, Bussel A, Chosidow O, Rabian C, Piette JC, Frances C. Extracorporeal photochemotherapy for chronic erosive lichen planus. Lancet 1998; 351: 805. PubMed

Kunte C, Erlenkeuser‐Uebelhoer I, Michelsen S, Scheerer‐Dhungel K, Plewig G. Treatment of therapy‐resistant erosive oral lichen planus with extracorporeal photopheresis (ECP). J Dtsch Dermatol Ges 2005; 3: 889–894. PubMed

Marchesseau‐Merlin AS, Perea R, Kanold J, Demeocq F, Souteyrand P, D'Incan M. Photopheresis: an alternative therapeutic approach in corticoresistant erosive oral lichen planus. Ann Dermatol Venereol 2008; 135: 209–212. PubMed

Elewa R, Altenburg A, Zouboulis CC. Recalcitrant severe erosive cutaneous lichen planus treated with extracorporeal photopheresis monotherapy. Br J Dermatol 2011; 165: 441–443. PubMed

Zingoni A, Deboli T, Savoia P, Bernengo MG. Effectiveness of extracorporeal photochemotherapy in the treatment of a case of refractory erosive lichen planus. J Dermatolog Treat 2010; 21: 119–121. PubMed

Guyot AD, Farhi D, Ingen‐Housz‐Oro S, Bussel A, Parquet N, Rabian C et al Treatment of refractory erosive oral lichen planus with extracorporeal photochemotherapy: 12 cases. Br J Dermatol 2007; 156: 553–556. PubMed

Chiesa‐Fuxench ZC, Gonzalez‐Chavez J. Extracorporeal photopheresis: a review on the immunological aspects and clinical applications. P R Health Sci J 2010; 29: 337–347. PubMed

Kuhn A, Aberer E, Bata‐Csorgo Z, Caproni M, Dreher A, Frances C et al S2k guideline for treatment of cutaneous lupus erythematosus ‐ guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2017; 31: 389–404. PubMed

Knobler RM, Graninger W, Graninger W, Lindmaier A, Trautinger F, Smolen JS. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A Pilot study. Arthritis Rheum 1992; 35: 319–324. PubMed

Wollina U, Looks A. Extracorporeal photochemotherapy in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 1999; 13: 127–130. PubMed

Richard MA, Saadallah S, Lefevre P, Poullin P, Buscaylet S, Grob JJ. Extracorporeal photochemotherapy in therapy‐refractory subacute lupus. Ann Dermatol Venereol 2002; 129: 1023–1026. PubMed

Boeckler P, Liu V, Lipsker D. Extracorporeal photopheresis in recalcitrant lupus erythematosus. Clin Exp Dermatol 2009; 34: e295–e296. PubMed

Morruzzi C, Liu V, Bohbot A, Cribier B, Lipsker D. Four cases of photopheresis treatment for cutaneous lupus erythematosus refractory to standard therapy. Ann Dermatol Venereol 2009; 136: 861–867. PubMed

Richter HI, Krutmann J, Goerz G. Extracorporeal photopheresis in therapy‐refractory disseminated discoid lupus erythematosus. Hautarzt 1998; 49: 487–491. PubMed

Wilfert H, Honigsmann H, Steiner G, Smolen J, Wolff K. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990; 122: 225–232. PubMed

Malawista SE, Trock DH, Edelson RL. Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. Arthritis Rheum 1991; 34: 646–654. PubMed

Menkes CJ, Andreu G, Heshmati F, Hilliquin P. Extracorporeal photochemotherapy. Br J Rheumatol 1992; 31: 789–790. PubMed

Hilliquin P, Andreu G, Heshmati F, Menkes CJ. Treatment of refractory rheumatoid polyarthritis by extracorporeal photochemotherapy. Rev Rhum Ed Fr 1993; 60: 125–130. PubMed

Poehlau D, Rieks M, Postert T, Westerhausen R, Busch S, Hoffmann K et al Photopheresis–a possible treatment of multiple sclerosis?: report of two cases. J Clin Apher 1997; 12: 154–155. PubMed

Rostami AM, Sater RA, Bird SJ, Galetta S, Farber RE, Kamoun M et al A double‐blind, placebo‐controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler 1999; 5: 198–203. PubMed

Besnier DP, Chabannes D, Mussini JM, Dupas B, Esnault VL. Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol Photoimmunol Photomed 2002; 18: 36–41. PubMed

Cavaletti G, Perseghin P, Dassi M, Cavarretta R, Frigo M, Caputo D et al Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing‐remitting multiple sclerosis. Neurol Sci 2006; 27: 24–32. PubMed

Gilliet M, Cozzio A, Burg G, Nestle FO. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005; 152: 531–536. PubMed

Mathur K, Morris S, Deighan C, Green R, Douglas KW. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. J Clin Apher 2008; 23: 144–150. PubMed

Lauchli S, Zortea‐Caflisch C, Nestle FO, Burg G, Kempf W. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 2004; 208: 278–280. PubMed

Durani BK, Bock M, Naher H. Extracorporeal photopheresis–treatment option in scleromyxedema? Hautarzt 2001; 52(10 Pt 2): 938–941. PubMed

Krasagakis K, Zouboulis CC, Owsianowski M, Ramaker J, Trautmann C, Tebbe B et al Remission of scleromyxoedema following treatment with extracorporeal photopheresis. Br J Dermatol 1996; 135: 463–466. PubMed

Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B et al Treatment of cutaneous T‐cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297–303. PubMed

Chiricozzi A, Faleri S, Lanti A, Adorno G, Lore B, Chimenti S et al Apheresis in the treatment of recalcitrant atopic dermatitis: case series and review of the literature. Eur J Dermatol 2014; 24: 545–550. PubMed